▁the ▁market ▁( now ▁only ▁available ▁as ▁an ▁investig ational ▁agent ) ▁due ▁to ▁serious ▁ad verse ▁events ▁such ▁as ▁t ors ades , ▁and ▁publication ▁bias ▁has ▁been ▁c ited ▁as ▁a ▁potential ▁partial ▁explanation ▁for ▁such ▁a ▁high ▁benefit . ▁ ▁Modern ▁pro kin etic ▁agents ▁such ▁as ▁met oc lo pr am ide , ▁er yth rom yc in ▁and ▁t eg aser od ▁have ▁little ▁or ▁no ▁established ▁effic acy ▁and ▁often ▁result ▁in ▁substantial ▁side ▁effects . ▁ ▁Sim eth ic one ▁is ▁of ▁some ▁value , ▁as ▁one ▁trial ▁suggests ▁potential ▁benefit ▁over ▁place bo ▁and ▁another ▁shows ▁equivalence ▁with ▁c is ap ride . ▁ ▁So , ▁with ▁the ▁somewhat ▁recent ▁advent ▁of ▁the ▁pro ton ▁p ump ▁in hib itor ▁( P PI ) ▁class ▁of ▁medic ations , ▁the ▁question ▁of ▁whether ▁these ▁new ▁agents ▁are ▁superior ▁to ▁traditional ▁ther apy ▁has ▁ar isen . ▁ ▁Currently , ▁P PI s ▁are , ▁depending ▁on ▁the ▁specific ▁drug , ▁F DA ▁indicated ▁for ▁er os ive ▁es oph agit is , ▁g astro es oph age al ▁re fl ux ▁disease ▁( GER D ), ▁Z ol ling er - E ll ison ▁synd rome , ▁er adic ation ▁of ▁H . ▁p yl ori , ▁du oden al ▁and ▁g astr ic ▁ul cers , ▁and ▁NS A ID - indu ced ▁ul cer ▁he aling ▁and ▁prevent ion , ▁but ▁not ▁functional ▁d ys pe ps ia . ▁However , ▁evidence -